Kindred Biosciences, Inc. (NASDAQ:KIN) has scheduled a conference call for 9th November 2020 at 4:30 PM Eastern Time to announce its 3Q20 financial results.
The conference call will also be webcast live under the investor relations section of the website www.kindredbio.com
Earnings Expectation
Kindred Biosciences, Inc. is expected to report third quarter earnings results, after market close, on Monday 9th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.3 per share from revenue of $ 0.56 million. Looking ahead, the full year loss are expected at $ 0.53 per share on the revenues of $ 41.24 million.
Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.
